Grant

Innovate UK award to OVM for clinical development of OVM-200

Oxford Vacmedix receives an Investor Partnership award from Innovate UK for the clinical development of lead cancer vaccine OVM-200. Oxford, UK _ 9 January 2025 Press Release – Innovate UK Award 09-Jan-25 Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, confirmed today the grant of a prestigious Investor Partnership award from Innovate UK for the clinical development of its lead cancer vaccine OVM-200. The award is made as part of the SME Round 6 p...
Read More

Oxford Vacmedix announces grant from Innovate UK for OVM-200 clinical trial

Prostate Cancer Research’s Proven Connect supports grant application and facilitates additional funding for the clinical development of OVM’s lead cancer vaccine, OVM-200. Oxford – 31st July 2024 Press Release – Oxford Vacmedix announces grant from Innovate UK for OVM-200 clinical trial Oxford Vacmedix (OVM), developing therapeutic cancer vaccines, announced today the grant of a prestigious non-dilutive Investor Partnership Award from Innovate UK, the UK’s innovation agency, to...
Read More
en_GBEnglish